[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immunoglobulin-deficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immunoglobulin-deficiency":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100484176","phase-1-ivig-vs-scig-in-cidp-100484176",false,"NCT05584631","IVIG vs SCIG in CIDP","The Influence of Body Composition on Immunoglobulin Disposition After Intravenous and Subcutaneous Administration","Inclusion Criteria:\n\n* Patients aged \\>18 years with a current diagnosis of CIDP (based on European Federation of Neurological sciences \u002F Peripheral Nerve Society CIDP diagnostic criteria).\n* 1:1 conversion of IVIG to SCIG (weekly dose conversion) must fall within 0.2-to-0.4 mg\u002Fkg dose for SCIG.\n\nExclusion Criteria:\n\n* Patients receiving IVIG for indications other than CIDP will be excluded.\n* Patients with liver impairment (elevations in liver enzymes of greater than 3 times the upper limit of normal) or reduced renal function (CrCl \\\u003C 50 mL\u002Fmin) will be excluded\n* Active malignancies\n* Diabetes\n* Myasthenia gravis\n* Immunodeficiency\n* Autoimmune disease","ALL","18 Years","65 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.",[27,28,29],"CIDP","Immunoglobulin Deficiency","Chronic Inflammatory Demyelinating Polyneuropathy",[31,32,33],"immunoglobulin","pharmacokinetics","obesity","RECRUITING","2025-12-10",{"date":37,"type":38},"2025-12-11","ACTUAL",{"date":40,"type":38},"2022-09-11",{"date":42,"type":21},"2026-12-01",{"name":44,"class":45},"Rutgers, The State University of New Jersey","OTHER"]